Release Date: December 30, 2016
Expiration Date: December 30, 2017
Media: Internet - based
This activity will focus on the evolution of immuno-oncology treatments and the evolving potential in treating hematologic malignancies and will include 2 expert video interviews. The expert faculty will discuss new data, provide perspective on how the evolving concepts may impact the future, and guide participants on potential application to clinical practice.
CME Activity Table of Contents
- CAR-T Cell Technology: Design and Rationale
- The Potential for CAR-T Cells in Clinical Practice for Hematologic Malignancies
- Safety and Toxicity Management of CAR-T Cell Technology: Pediatric and Adult Patients
- Coordinating Care Between Academic Centers and Community Practices
- Future of CAR-T Cell Technology
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists who treat patients with hematologic malignancies. Fellows, nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment of hematologic malignancies are also invited to participate.
At the conclusion of this activity, participants should be better prepared to:
- Describe the structure and function of the CAR and the mechanism of action of CAR T cells in lymphoma
- Review clinical trial evidence in acute lymphoblastic leukemia (ALL) and describe where CAR-T cell therapies might fit in the treatment landscape
- Review clinical trial evidence in other lymphoid malignancies and describe where CAR-T cell therapy might fit in the treatment landscape
- Identify and discuss the management of toxicities of CAR-T cell therapies
Faculty, Staff, and Planners' Disclosures
Jae H. Park, MD
Assistant Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Juno Therapeutics, Genentech; Consultant: Amgen, Novartis.
Daniel J. DeAngelo, MD, PhD
Director of Clinical and Translational Research, Adult Leukemia
Associate Professor of Medicine, Harvard Medical School
Disclosure: No relevant financial relationships with commercial interests
The staff of PER®, LLC have no relevant financial relationships with commercial interests.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
CME Provider Contact Information
Physicians’ Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)